Who we are
Penta ID Network
Penta Foundation Italy
Penta Foundation UK
Penta ID Innovation
News & Events
Work with us
Call for services
Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children >30 days and <18 years of age.
Three year outcomes in children treated with HAART before 3 months of age in the PENTA 7 trial.
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome
PENTA guidelines for the use of antiretroviral therapy 2004
72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 study
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens
Pharmacokinetics (PK) of once daily versus twice daily Lamivudine and Abacavir in HIV-1 infected children: PENTA 13